Hadassah

Hadassah Research Leads to Patent for Diabetes-Related Oral Delivery Technology

Thursday, Jan 22 2015

Oramed Pharmaceuticals Inc., focused on the development of oral drug delivery systems including an oral insulin pill based on Hadassah Medical Organization research, has received a patent from the Israel Patent Office for its invention, “Methods and Compositions for Oral Administrations of Exenatide.”

Eexenatide, a glucagon-like peptide-1 (GLP-1) analog, is a hormone which induces insulin release at increased glucose levels and causes a feeling of satiety, resulting in reduced food intake and weight loss. Currently, it is only marketed in injectable form. Oramed’s oral GLP-1 capsule, according to Oramed, could significantly increase compliance and become a valuable tool in the treatment of diabetes.

Oramed was founded in 2006 by Dr. Miriam Kidron, a senior researcher in the Diabetes Unit at Hadassah, who continues to serve as the company’s chief scientist. A pharmacologist and biochemist, Dr. Kidron earned her PhD in biochemistry from the Hadassah-Hebrew University and earned the Bern Schlanger Award for her work in diabetes research. Formerly a visiting professor at the Medical School at the University of Toronto, she is a member of the American, European, and Israeli diabetes associations.

Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Hadassah. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes, under an Investigational New Drug application with the United States Food and Drug Administration.

Read more

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Jan 10 2017

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.

READ MORE ›
alt_text

Monday, Jan 9 2017

Soldiers Rushed to Hadassah After Sunday's Terrorist Attack

On Sunday January 8, four soldiers were killed and 17 wounded, when a terrorist rammed his vehicle into them.

READ MORE ›
alt_text

Monday, Jan 9 2017

Prime Minister Netanyahu visits terror survivors at Hadassah Hospital

Prime Minister Benjamin Netanyahu and Health Minister Yaakov Litzman visited terror victims hospitalized at Hadassah Hospital Ein Kerem after a terrorist rammed his flatbed truck into a group of soldiers on an IDF cultural field trip in Jerusalem. Four were killed, and 11 patients underwent treatment at Hadassah hospitals: 9 at Ein Kerem and 2 at Mount Scopus.

READ MORE ›
alt_text

Friday, Jan 6 2017

World-First Newborn Intestinal Surgery Saves Baby Girl at Hadassah

A baby girl whose intestines formed outside of her abdomen was saved by a world-first surgical procedure following her birth at Hadassah Hospital Ein Kerem.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More